Aktienanalyse zu Vaxcyte Inc (PCVX)PCVXVaxcyte Inc

Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Vaxcyte Inc is a good buy right now, trading at $63.62 with a recent surge of over 60% following successful vaccine trial results. The RSI is currently at 43.406, indicating potential for upward momentum as it approaches oversold territory. The forward P/E ratio is at 0, suggesting that the stock is undervalued given its growth potential in the $3 billion to $6 billion adult pneumococcal vaccine market. However, the company is facing significant losses, with a projected net income loss of $320 million in Q1 2026, which is a primary risk to consider.